Smith & Nephew stock gains after FDA clears knee system

Smith & Nephew plc (GB0009223206) traded at GBX 1,027.50 on the London Stock Exchange on September 18, 2026, down 0.77 percent from the previous close. The company also secured US regulatory clearance for its LANDMARK Total Knee System, giving the stock a concrete product catalyst.

FDA clearance expands knee portfolio

GlobeNewswire reported on September 22, 2026, that Smith+Nephew received FDA 510(k) clearance and completed the first surgical cases with the LANDMARK Total Knee System. The product is designed to support a more personalized approach to total knee replacement by replicating healthy knee anatomy and natural motion.

The clearance matters because knee replacement is a core area of Smith & Nephew's orthopaedics business, while the first procedures provide an operating milestone rather than only a pipeline announcement. The release also cautions that statements about revenue growth, trading profit margins, market trends and the product pipeline are forward-looking.

Analyst target stays above price

MarketBeat's September 18, 2026 snapshot listed an average analyst price target of GBX 1,293.33 and a consensus rating of Hold, based on three Buy and six Hold ratings from nine analysts. The target was GBX 265.83 above the quoted price, a difference of 25.9 percent calculated from those two figures.

The comparison is mixed rather than one-sided: the target range ran from GBX 1,000 to GBX 1,600, so the quoted price was above the lower end while remaining below the average. MarketBeat also recorded a daily range of GBX 1,025.00 to GBX 1,041.50 and a 50-day range of GBX 1,008.50 to GBX 1,214.50 on September 18, 2026.

Stock valuation and trading data

The same September 18 market snapshot put Smith & Nephew's market capitalization at GBP 11.26 billion and trading volume at 5.40 million shares. The closing price of GBX 1,027.50 therefore came with a market value above GBP 11 billion, while the Hold consensus indicates that the average target does not translate into a uniform analyst view.

For investors, the key distinction is between product execution and valuation: FDA clearance creates a route to commercialization, but the company still needs adoption and revenue conversion for the product milestone to affect reported results.

Smith & Nephew stock closes at GBX 1,027.50

Smith & Nephew stock closed at GBX 1,027.50 on the London Stock Exchange on September 18, 2026, with a daily change of minus 0.77 percent. The quoted market capitalization was GBP 11.26 billion as of that snapshot.

More news and analyses on Smith and Nephew stock